Simulations Plus

Simulations Plus P/B

The P/B (Price-to-Book Ratio) of Simulations Plus (SLP) as of Sep 27, 2026 is 1.98. In the previous year, P/B (Price-to-Book Ratio) was 1.36 — a change of 46.18% (higher).

P/B

1.98

YoY

46.18%

Last updated:

P/B (Price-to-Book Ratio) of Simulations Plus is 2026 1.98 . P/B (Price-to-Book Ratio) of Simulations Plus was 2025 1.36 . It decreases by 46.18% higher compared to the previous year.

The Simulations Plus P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
7.76 USD
Jan 1, 2019
6.57 USD
Jan 1, 2020
1.59 USD
Jan 1, 2021
1.49 USD
Jan 1, 2022
1.39 USD
Jan 1, 2023
1.46 USD
Jan 1, 2024
1.36 USD
Jan 1, 2025
1.98 USD
The Simulations Plus P/B history
YEARP/BYoY
1.98+46.18%
1.36-6.80%
1.46+4.83%
1.39-6.99%
1.49-5.88%
1.59-75.85%
6.57-15.28%
7.76-19.16%
9.60-11.91%
10.89-14.08%
12.68-20.97%
16.04—
Access this data via the Eulerpool API
Get Free API Key

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Simulations Plus stock

P/B (Price-to-Book Ratio) of Simulations Plus is 1.98 in 2026.

P/B (Price-to-Book Ratio) of Simulations Plus changed from 1.36 to 1.98, representing a 46.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Simulations Plus since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Simulations Plus with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Simulations Plus

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Simulations Plus